Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: Meta-analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: It remains unclear how much various factors contribute to the placebo response. Aims: To estimate the therapeutic impact of follow-up assessments on placebo response in antidepressant trials. Method: Double-blind, placebo-controlled antidepressant trials that reported weekly changes in Hamilton Rating Scale for Depression (HRSD) scores over 6 weeks were selected. Included studies (n=41) were divided into those that conducted four, five or six follow-up assessments. Reductions in HRSD scores as a function of the different follow-up schedules were compared. Results: An extra follow-up visit at week 3 was associated with a 0.86 further reduction in HRSD score; an extra visit at week 5 was associated with a 0.67 further reduction. These effects represented approximately 34–44% of the placebo response that occurred over these time frames. Two additional visits were associated with twice the reduction in HRSD score than one, suggesting that the therapeutic impact of assessment visits is cumulative and proportional. A comparable therapeutic effect was also found in participants receiving active medication. Conclusions: Follow-up assessments in antidepressant treatment trials incur a significant therapeutic effect for participants on placebo, and this represents about 40% of the placebo response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
How expectancies shape experience.
(1999) · doi:10.1037/10332-000 · Cited by 639
Is there a delay in the antidepressant effect? A meta-analysis
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0201 · Cited by 250
Self-citationA Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158
The Naturalistic Course of Unipolar Major Depression in the Absence of Somatic Therapy
Posternak, M. A., Solomon, D. A., Leon, A. C., Mueller, T. I., Shea, M. T., Endicott, J., & Keller, M. B. (2006) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000217820.33841.53 · Cited by 113 · cited 1×
“Other investigators have provided independent confirmation of this estimate (Posternak & Zimmerman, 2001; Posternak et al, 2006).”
ResultSelf-citationBYERLEY, W. F., REIMHERR, F. W., WOOD, D. R., & GROSSER, B. I. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198804000-00005 · Cited by 80
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
St John's wort for major depression
Linde, K., Berner, M. M., & Kriston, L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000448.pub3 · Cited by 477
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O. (2014) · BMJ · doi:10.1136/bmj.g1888 · Cited by 334
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Burke, L. B., Farrar, J. T., Gilron, I., Jensen, M. P., Katz, N. P., Raja, S. N., Rappaport, B. A., et al. (2012) · Pain · doi:10.1016/j.pain.2012.03.003 · Cited by 285
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Cuijpers, P., Dekker, J., Hollon, S. D., & Andersson, G. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05021 · Cited by 261
Increasing placebo responses over time in U.S. clinical trials of neuropathic pain
Tuttle, A. H., Tohyama, S., Ramsay, T., Kimmelman, J., Schweinhardt, P., Bennett, G. J., & Mogil, J. S. (2015) · Pain · doi:10.1097/j.pain.0000000000000333 · Cited by 259
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?
Ioannidis, J. P. (2008) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-3-14 · Cited by 253
“Empirical evidence suggests also that much of the placebo effect in antidepressant trials is related simply to the number of patient visits during a trial [38].”
Placebo effects: clinical aspects and neurobiology
Oken, B. S. (2008) · Brain · doi:10.1093/brain/awn116 · Cited by 237
“Placebo effects are even affected by the number of patient–clinician interactions (Ilnyckyj et al., 1997; Paternak and Zimmerman, 2007).”
BackgroundZuranolone for the Treatment of Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., et al. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220785 · Cited by 192
Neuronal network plasticity and recovery from depression
Castrén, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1 · Cited by 190
Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004824 · Cited by 173
“Furthermore, despite several metaanalyses assessing the placebo response of pharmacological trials in depression [1,2,9,10] placebo response of transcranial magnetic stimulation has not been sufficiently explored.”
BackgroundRole of expectations in health
Colloca, L., & Miller, F. G. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328343803b · Cited by 161
Farrar, J. T., Troxel, A. B., Haynes, K., Gilron, I., Kerns, R. D., Katz, N. P., Rappaport, B. A., Rowbotham, M. C., Tierney, A. M., Turk, D. C., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.009 · Cited by 110
“In addition, there were not enough studies to examine other study related factors that might affect the response in treatment groups, including the number of follow-up visits and the amount of interaction with study staff [17], the use of concomitant medications [3], and the number of patients enrolled at specific tes…”
BackgroundYonkers, K. A., Lin, H., Howell, H. B., Heath, A. C., & Cohen, L. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0420 · Cited by 98
Dahlin, M., Andersson, G., Magnusson, K., Johansson, T., Sjögren, J., Håkansson, A., Pettersson, M., Kadowaki, Å., Cuijpers, P., & Carlbring, P. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2015.12.007 · Cited by 86
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87
Christmas, D., Steele, J. D., Tolomeo, S., Eljamel, M. S., & Matthews, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.080 · Cited by 57
“It is not possible to exclude the possibility that additional characteristics of VNS (e.g. additional clinic visits (Posternak and Zimmerman, 2007)) increase the potency of ‘non-specific’, or placebo, effects, but the follow-up schedule for VNS does not differ markedly from active follow-up for…”
BackgroundTakahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Zilcha-Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00293 · Cited by 53
Approval of esketamine for treatment-resistant depression
Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46
Esketamine Nasal Spray versus Quetiapine for Resistant Depression
(2024) · New England Journal of Medicine · doi:10.1056/nejmc2313230 · Cited by 1
Metadata
- Authors
- Posternak, M. A., & Zimmerman, M.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2007-04
- Volume
- 190
- Issue
- 4
- Pages
- 287-292
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2220387563
- Cited by
- 154
- References
- 7
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.